Medtronic vs Vertex Pharmaceuticals

Medtronic (MDT), health care, and Vertex Pharmaceuticals (VRTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Vertex Pharmaceuticals is worth $135.4B on the stock market and Medtronic $132.2B: Vertex Pharmaceuticals is valued at 2% more. Medtronic trades at 25.4 times earnings and Vertex Pharmaceuticals at 34.4; operating margins in their latest fiscal years were 17.8% and 34.8%. Over the past year Medtronic's share price has moved +2.06% and Vertex Pharmaceuticals's +23.5%.

Key facts

Medtronic market value
$132.2B
Vertex Pharmaceuticals market value
$135.4B
Medtronic P/E
25.4
Vertex Pharmaceuticals P/E
34.4
Medtronic revenue
$36.4BFY to 2026-04-24
Vertex Pharmaceuticals revenue
$12BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Medtronic vs Vertex Pharmaceuticals: every measure side by side
Measure Medtronic Vertex Pharmaceuticals
SectorHealth CareHealth Care
Country Ireland United States
Fiscal year ends2026-04-242025-12-31
Size
Market cap$132.2Blower$135.4Bhigher
Revenue$36.4Bhigher$12Blower
Earnings$4.8Bhigher$4Blower
Employees95,000higher6,400lower
Total assets$93Bhigher$25.6Blower
Valuation
P/E25.4lower34.4higher
P/S3.6lower11.3higher
P/B—6.5
Dividend yield—0.00%
Profitability
Operating margin17.8%lower34.8%higher
Balance sheet
Net assets$49.5Bhigher$18.7Blower
Total liabilities$43Bhigher$7Blower
Total debt$28B—
Cash on hand$1.9Blower$5.1Bhigher
Price change
Today+0.43%higher-0.68%lower
1 year+2.06%lower+23.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Medtronic / Vertex Pharmaceuticals). Who owns MDT · Who owns VRTX

Further comparisons

Learn

Questions and answers

Which is bigger, Medtronic or Vertex Pharmaceuticals?

By market value, Vertex Pharmaceuticals is the larger: $135.4B against $132.2B for Medtronic. By revenue in its latest fiscal year, Medtronic is the larger: $36.4B against $12B for Vertex Pharmaceuticals.

Which has the higher P/E ratio?

Vertex Pharmaceuticals: 34.4, against 25.4 for Medtronic. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Vertex Pharmaceuticals: 34.8%, against 17.8% for Medtronic. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Medtronic and Vertex Pharmaceuticals?

In their latest 13F filings, Ken Griffin holds both.

Cite this page

Funkfolio, “Medtronic vs Vertex Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/mdt-vs-vrtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.